Jairo Olivares, MD
Hematology & Oncology · Garland, TXNPI 1770520165
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,179 of the $2,425 with a category attached, or 89.9%. It is spread thinly across 39 manufacturers, the largest accounting for just 7.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $930 and has fallen 82.3% since, to $164 in 2025. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 119 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$185
- Pfizer$146
- Incyte Corporation$140
- Seagen Inc.$122
- Novartis$122
- AstraZeneca$115
- plus $2K from 33 others
Across 73 payments — averaging $2382.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$121K
- Array Biopharma Inc$43K
- Astrazeneca UK Limited$10K
What the payments were for
- Food & beverage$2,17990%
- Education$24610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 9 | $185 |
| Pfizer | 9 | $146 |
| Incyte Corporation | 5 | $140 |
| Seagen Inc. | 5 | $122 |
| Novartis | 6 | $122 |
| AstraZeneca | 5 | $115 |
| Rigel Pharmaceuticals, Inc. | 6 | $105 |
| AbbVie | 4 | $100 |
| Gilead(2 entities) | 5 | $99 |
| E.r. Squibb & Sons, L.L.C. | 6 | $91 |
| Eisai Inc. | 4 | $89 |
| Puma Biotechnology, Inc. | 4 | $86 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $77 |
| Johnson & Johnson(2 entities) | 4 | $74 |
| Daiichi Sankyo Inc. | 3 | $63 |
| Stemline Therapeutics Inc. | 3 | $57 |
| Bayer | 3 | $55 |
| Amgen | 2 | $54 |
| Bristol Myers Squibb | 2 | $54 |
| Astellas Pharma US Inc | 3 | $51 |
| Myovant Sciences Inc. | 2 | $48 |
| Sanofi | 2 | $40 |
| Global Blood Therapeutics, Inc. | 2 | $38 |
| Genentech USA, Inc. | 2 | $36 |
| Pharmaessentia USA Corporation | 1 | $34 |
| Karyopharm Therapeutics Inc. | 2 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Tesaro, Inc. | 1 | $24 |
| Mirati Therapeutics, Inc. | 1 | $23 |
| Tersera Therapeutics LLC | 1 | $22 |
| GSK | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Dova Pharmaceuticals | 1 | $18 |
| Medtronic | 1 | $12 |
| Acrotech Biopharma Inc. | 1 | $12 |
| Dendreon Pharmaceuticals LLC | 1 | $12 |
How this compares
$2,425 in reported general payments places this provider in the 40th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Garland
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.